Moderate hypothermia vs normothermia not tied to improved mortality in cardiogenic shock: JAMA

France: A recent study reveals that the early application of moderate hypothermia for 24 hours versus normothermia does not significantly increase survival in patients with cardiogenic shock receiving venoarterial ECMO. The study was published in the Journal of the American Medical Association (JAMA) on February 1, 2022. 

"30-day mortality was not significantly lower in those treated with moderate hypothermia during venoarterial extracorporeal membrane oxygenation (ECMO) (42%) compared to those held at normothermia during ECMO (51%)," Bruno Levy, Université de Lorraine, Nancy, France, and the team wrote in their study. "Adverse events, such as nosocomial infections and bleeding, occurred at a similar rate in the hypothermia and normothermia groups, however, the hypothermia group required more RBC transfusions.

Dr. Levy and the team conducted the study with an objective to determine whether early use of moderate hypothermia (33-34 °C) compared with strict normothermia (36-37 °C) improves mortality in patients with cardiogenic shock receiving venoarterial ECMO.

For this purpose, they conducted a randomized clinical trial of patients who had been endotracheally intubated and were receiving venoarterial ECMO for cardiogenic shock for <6 hours. The study was set in the intensive care units at 20 French cardiac shock care centers between October 2016 and July 20. 374 were randomized out of 786 eligible patients to receive early moderate hypothermia (33-34 °C; n = 168) for 24 hours or strict normothermia (36-37 °C; n = 166). The primary outcome was mortality at 30 days.